Loss of the cortisol response to naltrexone in Alzheimer's disease

Biol Psychiatry. 1988 Apr 1;23(7):726-33. doi: 10.1016/0006-3223(88)90057-1.

Abstract

The administration of a single dose of the opiate antagonist naltrexone (NT) was accompanied by significant elevations in plasma cortisol in normal elderly subjects; in contrast, the cortisol response to NT was absent in individuals of comparable age with Alzheimer's disease (AD). The differential effect of AD on the cortisol response was not accompanied by a significant group difference in plasma prolactin in response to NT administration. Furthermore, this differential cortisol response to NT was not associated with any evident differences in age, sex ratio, plasma levels of naltrexone or its major metabolite beta-naltrexol, or with differences in measures of nonspecific stress, such as plasma free MHPG, pulse, or blood pressure, between the two groups. The absence of the well-characterized cortisol response to NT in AD, together with other reports of abnormal responses to other pharmacological challenges, suggests that neuroendocrine abnormalities might be an important concomitant and possibly a central contributor to the pathophysiology of Alzheimer's disease.

Publication types

  • Clinical Trial

MeSH terms

  • Aged
  • Alzheimer Disease / blood
  • Alzheimer Disease / drug therapy*
  • Blood Pressure / drug effects
  • Clinical Trials as Topic
  • Double-Blind Method
  • Female
  • Humans
  • Hydrocortisone / blood*
  • Male
  • Methoxyhydroxyphenylglycol / blood
  • Naltrexone / adverse effects
  • Naltrexone / therapeutic use*
  • Prolactin / blood

Substances

  • Methoxyhydroxyphenylglycol
  • Naltrexone
  • Prolactin
  • Hydrocortisone